Phenotype standardization for statin-induced myotoxicity - Wikidata - wikimedia - TriplyDB

Phenotype standardization for statin-induced myotoxicity

Phenotype standardization for statin-induced myotoxicity

http://www.wikidata.org/entity/Q27020935

about

PCSK9 inhibitors in the prevention of cardiovascular disease Statin-Associated Muscle Adverse Events: Update for clinicians PharmGKB summary: very important pharmacogene information for RYR1 Curcumin: An effective adjunct in patients with statin-associated muscle symptoms?Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Statin intolerance - a question of definition.Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome.Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4?Big Data Transforms Discovery-Utilization Therapeutics Continuum.Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.Statin intolerance: diagnosis and remedies.Phenotyping Adverse Drug Reactions: Statin-Related Myotoxicity.The EuroMyositis registry: an international collaborative tool to facilitate myositis research.Advances in the Pharmacogenomics of Adverse Drug Reactions.Expert opinion: the therapeutic challenges faced by statin intolerance.Development and validation of algorithms for the detection of statin myopathy signals from electronic medical records.Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.Statins, Muscle Disease and Mitochondria.Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report.Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?".Pharmacogenetics in Cardiovascular Medicine.Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.A common missense variant of LILRB5 is associated with statin intolerance and myalgia.Biomarkers of adverse drug reactions.Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium.Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.Statins everyday versus alternate days: Is there a difference in myalgia rates?Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects

P2860

Q28071452-50FAD503-A9F4-4905-B29A-71A0F87720FE Q28074144-E788BFE7-88F8-46E5-885E-797FEE7F5011 Q28074804-1F4B2800-2F19-4AC4-9BCA-AC185F1E9987 Q28075647-57FF392F-9149-497B-893E-CA3BF567E4F8 Q28083004-0F2F5CFF-160C-4DBA-BA73-AFC4414DB2B9 Q30245218-B57403B8-2817-4B7C-9648-7F8DF59D5B74 Q33588629-0028330D-7E32-4AEE-838C-134FAA700147 Q35088411-1E7D8870-4EDC-46C8-A587-53FCCE4AB9C8 Q35926778-E41DABCC-5487-42AB-AA65-2D64F26BB97E Q37612171-EF65CCAC-3B8A-4B2F-956F-E3FB37D6D00F Q38430744-12D4C144-DE99-4D2D-8CE4-3F3568652CE2 Q38573568-11318A94-40D2-4ED8-98B1-AB56B2202D07 Q38601741-238AE846-17F6-4FB7-AD11-211D9D007084 Q38663764-86C64ABC-7446-420C-AA61-EF732BBD294C Q38851603-CC04342D-3D4A-40A8-894C-D2314F30DF8A Q39319994-BEDFC6AC-FF5D-4E3F-AE14-A55B5EB7B87A Q40759624-96C48126-64FE-48D1-85C6-3A01833A35D9 Q41552418-BB0F9DBA-FBFE-4614-8834-F1FE258F7717 Q42714702-46296634-55AF-49D5-9E2E-B680607878C3 Q42954035-29AA6062-34DC-4EBA-82DC-0388E3D5D8CC Q47130405-ED8A2003-872B-4303-A99C-89A94E7253A5 Q47676842-32C6060C-2DA2-41F8-A6AF-7B493E330943 Q47747535-D7401C59-8BF2-485F-A9A8-5788DD4F7FF3 Q47928481-E5E4AB6C-C1DB-43C7-94F1-072AAB9C965B Q51752364-9CB66B4C-6395-47B4-AF8F-227090941B77 Q52688656-2AD80F3F-9335-4B07-9ABC-386D37103CCA Q56975988-15802CDE-AF8F-4F06-9368-51E47EDB96D8 Q59126269-9C0580EC-43E7-4A6B-9D07-A5F449BF9D00

P2860

Phenotype standardization for statin-induced myotoxicity

http://www.wikidata.org/entity/Q27020935

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phenotype standardization for statin-induced myotoxicity

@ast

Phenotype standardization for statin-induced myotoxicity

@en

Phenotype standardization for statin-induced myotoxicity

@nl

type

label

Phenotype standardization for statin-induced myotoxicity

@ast

Phenotype standardization for statin-induced myotoxicity

@en

Phenotype standardization for statin-induced myotoxicity

@nl

prefLabel

Phenotype standardization for statin-induced myotoxicity

@ast

Phenotype standardization for statin-induced myotoxicity

@en

Phenotype standardization for statin-induced myotoxicity

@nl

P1433

Q27020935-AB333DFA-3911-4ABE-9568-8B1DB044C447

P1476

Q27020935-94029FD9-22C0-4475-B44F-AAE354C2EE11

P2093

Q27020935-24C57BEC-22AF-433B-8020-7E970B1F8F7E

Q27020935-28B63DE7-6340-4F53-A198-CDF9F73F4939

Q27020935-2BD4385C-1FE7-4555-A4DF-89D87866C259

Q27020935-570C6459-6F42-4D40-AB61-F4A9FD22575A

Q27020935-655760C7-55BB-4926-9401-4B8E943095A3

Q27020935-68DFD5CE-0A6E-4F7D-B7F1-CF7AB9A890A0

Q27020935-6D000EAF-DF95-49DE-B0A0-15844A5B614F

Q27020935-72EF86F6-6B4B-44FB-B604-FCB0323EFF25

Q27020935-8EE147AA-20DB-4D48-92F7-DA06C6DD53C0

Q27020935-AB706B0C-BED2-4DEC-AB94-2CC42913639B

P275

Q27020935-367DE719-F067-4F6A-BC1C-2ACA79B2A019

P2860

Q27020935-07007180-C0A3-48F0-B56F-8D08FB1795F0

Q27020935-0823C4BE-3536-42B0-8477-CC6DE98247DF

Q27020935-08A75F84-3915-4198-A4F6-2479B827D4F8

Q27020935-097F4FD1-3AED-4F5A-8A8D-05F338675CAF

Q27020935-0B3A7296-6E7F-4308-911A-AA58C79925D9

Q27020935-0BE539FF-71A8-434B-9A7B-F934DF1AA04D

Q27020935-0C52523C-C02C-4256-A4BD-E284313AB1D2

Q27020935-0C9ADE81-7005-445A-9694-00BA6D72E0CD

Q27020935-0E856A8D-2910-495E-8A4B-2DAFC21FBDE2

Q27020935-108CCF24-C92B-426E-88D4-8CF5E23DD6B2

P2888

Q27020935-D2F627A7-3970-45E9-9885-5C9AC967C03C

P304

Q27020935-90220C2A-9B5C-4D76-A1B4-2889DF40EA18

P31

Q27020935-914F0DD1-03E1-426E-8D52-1DC770BB5A25

P3181

Q27020935-DBFF789B-93ED-4B70-B247-5E54FAAD5527

P356

Q27020935-23502DA8-809F-444F-9880-73F3E539C72C

P407

Q27020935-F9AB8C11-A0B9-4211-8EED-23D899E8E304

P433

Q27020935-120EAC28-D5FE-416D-A4E4-72BE42E76046

P478

Q27020935-2192EF95-C588-48A7-8033-B5F55B3EB0AA

P50

Q27020935-25D0EBCB-600A-4891-AE8A-43A9989E8A76

Q27020935-756067F1-BAFC-4D3D-8ECB-701F94A8A33D

Q27020935-7D5D4CE8-AE5A-48C5-8357-97C440B0A658

Q27020935-8B4E4778-9EE0-4CCE-A1BA-4CCCE254C1DF

Q27020935-A0754A5C-C7E6-407D-B8BC-1FE78A014A3F

P577

Q27020935-31D29584-7E0F-49EE-B1B2-F73F61CC1B3B

Q27020935-7549B18A-D206-4EAB-BEA2-05E71711F304

P5875

Q27020935-ADBC421F-B4A6-4A38-A964-BD92F96F1844

P6179

Q27020935-EF586B6A-4BE2-4C38-B226-1D690881D5DD

P698

Q27020935-C0CC6D46-0F6D-455F-9564-0A620F66AE02

P921

Q27020935-8C12100A-5DA4-49A7-AF38-CBEE0401D0A3

P932

Q27020935-16C02934-C0DD-4F6E-BC44-C3B6A25E7795

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Phenotype standardization for statin-induced myotoxicity

@en

P2093

A Alfirevic

http://www.w3.org/2001/XMLSchema#string

A H Maitland-van Der Zee

http://www.w3.org/2001/XMLSchema#string

A Hanson

http://www.w3.org/2001/XMLSchema#string

B M Psaty

http://www.w3.org/2001/XMLSchema#string

D Neely

http://www.w3.org/2001/XMLSchema#string

D Voora

http://www.w3.org/2001/XMLSchema#string

J Armitage

http://www.w3.org/2001/XMLSchema#string

J Fahy

http://www.w3.org/2001/XMLSchema#string

K M Bloch

http://www.w3.org/2001/XMLSchema#string

Q-Y Yue

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

P2860

SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Statin safety: an overview and assessment of the data--2005.

HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients.

P2888

P304

470-476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2224406

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2014.121

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Munir Pirmohamed

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262915405

http://www.w3.org/2001/XMLSchema#string

P6179

1002491515

http://www.w3.org/2001/XMLSchema#string

P698

24897241

http://www.w3.org/2001/XMLSchema#string

P921

muscular disease

P932

4172546

http://www.w3.org/2001/XMLSchema#string